Active, not recruitingPhase 3NCT05325593
Romiplostim Plus Dexamethasone vs Dexamethasone in Patients With Newly Diagnosed Primary Immune Thrombocytopenia
Studying Autoimmune thrombocytopenia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
- Principal Investigator
- Charlotte BradburyCentre for Trials Research College of Biomedical & Life Sciences Cardiff University
- Intervention
- romiplostim plus dexamethasone(drug)
- Enrollment
- 129 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2022 – 2026
Study locations (30)
- IRCCS AOU di Bologna, Seràgnoli Institute of Hematology, Bologna, Italy
- ASST Fatebenefratelli Sacco - Ospedale L. Sacco, Milan, Italy
- Grande Ospedale Metropolitano Niguarda, Milan, Italy
- Azienda Ospedaliero-Universitaria Policlinico Umberto I / SAPIENZA Universitá di Roma, Rome, Italy
- Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Rome, Italy
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy
- Hospital del Mar, Barcelona, Barcelona, Spain
- Centre Sociosanitari Sant Jordi de la Vall D'Hebron, Barcelona, Barcelona, Spain
- Complejo Asistencial Universitario de Burgos, Burgos, Burgos, Spain
- Complejo Hospitalario Universitario A Coruña, A Coruña, Coruña, Spain
- Hospital Universitario Virgen de las Nieves, Granada, Granada, Spain
- Hospital General Universitario Gregorio Marañón, Madrid, Madrid, Spain
- Compejo Hospitalario La Paz, Madrid, Madrid, Spain
- Hospital Universitario Fundación Alcorcon, Madrid, Madrid, Spain
- Hospital Universitario Morales Meseguer, Murcia, Murcia, Spain
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05325593 on ClinicalTrials.govOther trials for Autoimmune thrombocytopenia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT07559331High-Dose Dexamethasone Combined With Orelabrutinib Versus High-Dose Dexamethasone Combined With Placebo in Adult Patients With Newly Diagnosed Primary Immune ThrombocytopeniaShandong University
- RECRUITINGPHASE2NCT07362199Anti-CD38 Monoclonal Antibody Combined With Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)Institute of Hematology & Blood Diseases Hospital, China
- RECRUITINGPHASE2NCT07362238Daratumumab Versus Rituximab in the Management of Pediatric Primary Immune Thrombocytopenia (ITP)Institute of Hematology & Blood Diseases Hospital, China
- RECRUITINGEARLY PHASE1NCT07441525UCAR-T Targeting CD19/BCMA in Subjects With Autoantibody-Mediated Autoimmune Benign Hematological DiseasesUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology
- RECRUITINGPHASE2NCT07234019Rituximab Combining Anti-CD38 Monoclonal Antibody Versus Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)Institute of Hematology & Blood Diseases Hospital, China
- RECRUITINGPHASE2NCT07297563Anti-CD38 Monoclonal Antibody Versus Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)Institute of Hematology & Blood Diseases Hospital, China
- RECRUITINGPHASE2NCT07294365A Study of DZD8586 in Adults With Primary Immune Thrombocytopenia (ITP) (TAI-SHAN11)Dizal Pharmaceuticals
- RECRUITINGPHASE2NCT07104565Study to Assess the Safety and Tolerability of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell DisordersIncyte Corporation